Clinical Trial Update: Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on the safety and tolerability of an mRNA vaccine encoding tumor-specific circular RNA antigens in combination with an anti-PD-1 monoclona…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Anti-PD-1 Monoclonal Antibody
• mRNA vaccine encoding tumor-specific circular RNA antigens

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Solid Tumor | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING